A study published in the British Journal of Pharmacology on 3 March, led by University of Queensland researchers Associate Professor Trent Woodruff and Dr John Lee, has found the drug “PMX205” extends the life of mice that have a SOD1 mutation, when administered before or during very early disease onset. More studies are now underway to determine the safety of PMX205 before it can be tested in humans. 'Pharmacological inhibition of complement C5a-C5a1 receptor signalling ameliorates disease pathology in the hSOD1G93A mouse model of amyotrophic lateral sclerosis' tttp://onlinelibrary.wiley.com/doi/10.1111/bph.13730/full
Postive results for PMX205 in mice with SOD1 mutation
Latest News
Keep Connecting with Communication Aids this Speech Pathology Week 2026
MND can affect the nerves and muscles used for communication including speaking, facial expressions, gestures, and swallowing. Approximately, 80% of p...
Top 5 Frequently Asked Questions from July 2026
Each month the MND InfoLine receives a wide range of enquiries from people living with MND, their families, and health professionals. We have rounded...
Dying to Know Day is about Starting Important Conversations
Dying to Know Day (8 August 2026) is a time for everyone to have important conversations about death and dying with purpose, love, and a sense of lega...
Vale Bob Montgomery
We are deeply saddened to hear of the sudden passing of Bob Montgomery. For many years, Bob dedicated himself to raising vital funds and awareness for...